LegalAug 6, 2026, 04:11 PM
Lisata Therapeutics Sues Kuva Labs After Merger Termination
AI Summary
Lisata Therapeutics, Inc. terminated its merger agreement with Kuva Labs Inc. on July 24, 2026, citing Kuva's failure to secure sufficient financing. The company subsequently initiated legal action against Kuva on July 31, 2026, seeking a $2 million termination fee and damages for willful breach. Concurrently, Lisata reported a Q2 2026 net loss of $(2.9) million, held $10.4 million in cash, and expressed substantial doubt about its ability to continue as a going concern, prompting its board to review strategic alternatives.
Key Highlights
- Merger agreement with Kuva Labs Inc. terminated on July 24, 2026.
- Company filed a lawsuit against Kuva Labs on July 31, 2026.
- Seeking $2 million termination fee and damages for willful breach.
- Cash and cash equivalents were $10.4 million as of June 30, 2026.
- Reported Q2 2026 net loss of $(2.9) million, compared to $(4.7) million in Q2 2025.
- Management expressed substantial doubt about continuing as a going concern.
- Board is reviewing strategic alternatives, including acquisition or liquidation.
Price Impact
More from LSTA